About OncoOne – our Team and our Vision
United in developing breakthrough cancer therapeutics
Cancer remains a leading cause of death worldwide, accounting for nearly 10 million lives taken in 2020, or nearly one in six deaths (WHO, International Agency for Research on Cancer). Although new therapies have demonstrated success in treating this widespread disease, critical and urgent issues including the development of resistance mechanisms, off-target cytotoxicity and lack of efficacy remain.
In an effort to contribute to the global fight against cancer, OncoOne is leveraging our proprietary drug development know-how to create first-in-class, novel, and highly potent therapeutics in order to treat underserved patients suffering from solid tumor cancers.
As a business model, OncoOne intends to ensure that we strive to apply state-of-the-art technologies and the highest possible quality standards in order to continue growing a successful and continuously evolving life science company.
Our Founders & Management Board
The Pioneers of oxMIF
OncoOne was founded in June 2018 by Randolf Kerschbaumer, Michael Thiele and Alexander Schinagl. Our founders have a long history in industrial drug development and oncology research. Each member of the management team has successfully contributed to the development of GMP-grade drug substances, patents and scientific publications. Our management team is comprised of professionals experienced in science management, leading networks of innovation by external collaborations and performing first-class in-house laboratory work.
OncoOne’s leadership team discovered that the macrophage migration inhibitory factor (MIF) oxidized at sites of inflammation, such as a tumor, arthritic joint, or asthmatic lung. They discovered and named this disease-related isoform of MIF the oxidized migration inhibitory factor (oxMIF) and together with the rest of the OncoOne team are working on first- and best-in-class therapeutics targeting this well-researched cytokine.
Our team is highly committed to our shared goal of developing breakthrough cancer therapeutics. As our company continues to grow, we are looking for individuals with a passion for science who want to join our team and bring new solutions to underserved indications.
Scientific Advisory Board
Head offices
in Boston (USA) and Vienna (Austria)
Employees
a diverse team across the globe with a united mission